Friday, 22 Nov 2019

Biologic/Novel Rx

Datesort ascending Type Title Save
04 Aug 2019 Social Measures used to limit costs & utilization of expensive biologics: 1) Generics 1st requirement; 2) Pre-authorization; 3) limited (6-9 mos) approval w/ proof of benefit; 4) 30 day supply; 5) preferred tiered drugs; & 6) utilize less expensive providers https://t.co/2HRrJn87AY
29 Jul 2019 Social Measures used to limit costs & utilization of expensive biologics: 1) Generics 1st requirement; 2) Pre-authorization; 3) limited (6-9 mos) approval w/ proof of benefit; 4) 30 day supply; 5) preferred tiered drugs; & 6) utilize less expensive providers https://t.co/2HRrJn87AY
27 Jul 2019 Social The FDA Arthritis Advisory Committee voted 10-7 in favor of approving the to consider the antifibrotic drug, nintedanib for the treatment of systemic sclerosis-associated interstitial lung disease (SSc-ILD) https://t.co/UNlpQNJAim
26 Jul 2019 Social Samsung Bioepsis has announced an update to the EU product label for its adalimumab biosimilar IMRALDI - adding the drug can be stored in non-refrigerated conditions (up to 25˚C or 77F) for up to 28 days https://t.co/nGgxZDBQyC
25 Jul 2019 Social FDA has approved Ruxience (rituximab-pvvr; Pfizer), a biosimilar to Rituxan for use in NHL, CLL, granulomatosis w/ polyangiitis (GPA) & microscopic polyangiitis;(NOT RA) THis is the 2nd RTX biosimilar. https://t.co/GuVG6S980j
24 Jul 2019 Social FDA has approved a new biosimilar Hadlima (adalimumab-bwwd), from Samsung Bioepis, for the same indications as Humira (RA, pJIA, PsA, AS, Crohn’s, UC, plaque psoriasis), but the drug won't be available in the U.S. until June 2023. https://t.co/h4oqwFjR0c
24 Jul 2019 News FINCH2: Filgotinib in Biologic Refractory Rheumatoid Arthritis
15 Jul 2019 News Rituximab Safety Concerns when Used in anti-TNF Refractory RA
15 Jul 2019 Social Do biologics work in relapsing polychondritis? French cohort of 41 pts use 105 biologics (TNFi=60; TCZ 17; anakinra 15; RTX 7; ABA6). While 63% resp in 1st 6 mos (on pred!), a complete response rate was 19.0%. Steroid sparing variable, high infx rates. https://t.co/Ff9KULlKVD
28 Jun 2019 Social FDA has announced that on July 25th it will hold an Arthritis Advisory Committee Meeting to discuss Boehringer Ingelheims application for Nintedanib use in systemic sclerosis-associated interstitial lung disease (SSc-ILD) https://t.co/z4uLJ8hdyX
24 Jun 2019 Social "Therapeutic Update: Biosimilars in Rheumatology" video series features nine experts talking about biosimilars, sponsored by Sandoz, Inc. Visit RheumNow to watch: https://t.co/1vmnEJqOSi #sponsored #biosimilars
21 Jun 2019 Social RT @LCalabreseDO: Give me your take for my next ED in @HealioRheum on DTC-Direct to-consumer adverstising of Drugs/Biologics (as seen on na…
21 Jun 2019 Social Hear nine experts talk about biosimilars in “Therapeutic Update: Biosimilars in Rheumatology”, a video series brought to viewers by Sandoz. Now available on RheumNow. https://t.co/1vmnEJqOSi #sponsored #biosimilars https://t.co/EXf19NB6g8
20 Jun 2019 News No Difference Among Biologics in Arthroplasty Infectious Risk
18 Jun 2019 News Is Methotrexate Necessary with Tofacitinib?
17 Jun 2019 Social Safety and Immunogenicity is one of nine educational videos available in the "Therapeutic Update: Biosimilars in Rheumatology" video series, sponsored by Sandoz, Inc. and now available on RheumNow. https://t.co/1vmnEJqOSi #sponsored #biosimilars
29 May 2019 Social FDA has approved the worlds most expensive drug - $2.1 million - Zolgensma (onasemnogene abeparvovec-xioi), a gene therapy for spinal muscular atrophy (SMA) that affects 1 in 11,000 newborns https://t.co/hHuymQ3sjV
28 May 2019 News Upadacitinib Monotherapy in MTX-IR Rheumatoid Arthritis
28 May 2019 News Predictors of Serious Infections with Rituximab
21 May 2019 News Nintedanib May Benefit Systemic Sclerosis Related Interstitial Lung Disease